презентация для правления (Id 1648) пм графики в картинках

  • Published on
    28-May-2015

  • View
    878

  • Download
    1

Embed Size (px)

Transcript

  • 1. ID 1648 (): : ..: ..: 5 2011 .: .., ..

2. ( -) ( ) ( , . .. , . ) , , . , ( 5-7 ) - 21/12/2010 07/02/2011 -1 14/06/2011 -2 , - - 2015 .: : : 6 687. . 1 280 . . EBITDA: 1 408 . . IRR : 37% : IRR : 17%/49%2,2 2 3. , - , ( .) 2016 .17%2% 81% , 2010 . - 30%5% 5%44% () 87 % 27% 41% 4% 4% 9% 5%14% 2% 2%8% 28%2% 2%8% 3 4. , . . , . . 80.030 CAGR = 10% 68.2 70.024.425 22.160.02018.9 46.617.4 50.0 16.315.215 40.0201028.6 2016 30.010 20.0510.5 10.0 4.26 4.61.8 3.500.0 20072008 2009 20102011 2012 - - C 2010 . 2016 , . .8% 2.33,4%2.3 21% 24% 68.228.6 55% : IMS Health, Pharmexpert, 4 5. 100 . . (2009 .) 1 , $ (2009 .) 1000875 926300 260 - 200122500119 () 306301 260 10026% 10 700 : NHLBI (National Heart, Lung and Blood Institute), American Heart Association, World Heart Federation, British HeartFoundation, WHO, Eurostat, , .- , , 100 . . (2009 .) (2009 .) 300 27270%80% ()60% 54%200 15824% 9840%26% 28% 20% 10020% 27 500% : World Health Organization, September 2010- 100 . . 60 1 . , $49 600 479 422 385 * *40 29400 356321 20201213% 200 5 00 : SEER, CDC, Globocan, . * 100000 , , ( , ..) 5 6. GMP 2004 - - .. 1997 400 . . - 720 2002 - GMP , . . 2007 - -5 400 240 2 . . 95 25 140 200720082009 20102011 125 . 200 29 . 70% , 30% - 2002 2007 80% , 2007 20% - Stada6 7. GMP , 1995 1997 - . , . 1997 2007 . , -, . 2008. / - ", . 1997 . - . 1994 .. 2008 . 1973. . . , 1975 . 2004 . 1975 7 8. 100% - 855,8 . . 1 280,3 . . 424,5 . . + 100% 49,99% 1 704,8 . . 50,01%100% 1 534,8 . . 855,8 . . 8 9. tag-along 2 drag-along 13- Drag-along : 2012 ( 2014 ) 3,4 . . 2014 2014 10% 2015 35% call 1 2016 17%9 10. : 2016-2018 ( GMP- ): 2014 , GMP- drag-along call 10 11. . .2013 20142015201620172018 2019 2020 2 032 4 913 6 6878 485 10 43612 067 12 567 12 874EBITDA303 1 177 1 752 2 400 3 493 4 5284 8004 928 (57)688 1 0671 5852 491 3 3863 7333 835 IRR : 37%IRR : 17% / 49%NPV@ 30% = 1 172. . IRR 0 -15% -10%-5% 0%5% 10%15%-20%21%30% 37% 43% 48% 52%56%-15%22%32% 39% 45% 50% 54%58%-10%24%33% 40% 46% 51% 56%60% -5%25%35% 42% 48% 53% 57%61%0%26%36% 43% 49% 54% 59%63%5%28%37% 45% 51% 56% 60%64% 10%29%39% 46% 52% 57% 62%66% 15%30%40% 47% 53% 59% 63%67% 20%31%41% 49% 55% 60% 65%69% 11 12. 120 . ., 10% 2017 2010 2 (IRR 17% / 49%) , , : , 15% 12 13. 13 14. 575 1172 - n-3- 560, 895, 1554 560 , 895 ( , 1554 , 1864 1864 ) 14 15. 1 535 . 7 : 2 5 7% : 2.17% 2.75% () - 3,44% () 1.25% ommitment fee ( ) 1% , , G.M.PROJECT 15 16. 16 17. 65 135 111 295 ( . . 1 313 ) 436 502 1 089. : 3 946 . . 17 18. ,( ( .)) . (, , , , .) 18 19. - % , 20%18% 18% : 17% 14%15% 1) - 15% 12%12%11% ( 10% ) 2) 5% (, , ): , 0% , 2013 2014 201520162017 2018 2019 2020 POS (, , .) : 1 800 1600 1625 1590 159015901 600( )1 4001 2001199 1 000. .812 800 600 400280106 200 -2012 2013 2014 2015 2016 2017 2018 2019202019 20. , , Al2O3 ( . ) 8-10 . , 1-2 . 10-100 ( . ). drug delivery, namely nano toxicity, bio Fig. 1 : TEM image showing highly porous high stability, and a compatibility, structure of silicon and porous structure useful for hydrophilic 7 . Using tailoring the encapsulation of drugs. hydro fluoric acid-based solutions, nanometer , size pores with exceptionally high aspect 10 be generated in silicon wafers, ratios can , chips or particles, and with a high degree of still pure control. The resultant material is ( . ) Silicon- properties and scopesilicon, but it behaves very differently toResearchers have now discovered a method tonano-porous bulk silicon; one importantexample is that it becomes strongly 20make composite photonic crystals of porous